Jonathan Kirk

Jonathan Kirk

Auto-generated profile, based on publicly available information

Jonathan Kirk

Center for Cardiovascular Research, Department of Medicine, University of Chicago, Chicago, IL (M.M.D., J.A.K.).

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2015 in Nature
Verified
Journal Article
Open access
PDF file
DLDong I. Lee
Dong I. Lee
GZGuangshuo Zhu
Guangshuo Zhu
TSTakashi Sasaki
Takashi Sasaki
GCGun-Sik Cho
Gun-Sik Cho
NHNazha Hamdani
Nazha Hamdani
DKDavid A. Kass
David A. Kass
The inhibition, in mice, of the phosphodiesterase PDE9A, which specifically regulates natriuretic-peptide-coupled cGMP signalling, is independent of nitric oxide and is upregulated in failing human hearts, and can reverse pre-established stress-induced heart disease. Work in animals has shown that inhibition of phosphodiesterase type 5A (PDE5A) with, for example, Viagra, can protect the heart from pathological stress by preventing the degradation of nitric-oxide-generated cGMP. However, nitric oxide signalling is often depressed in cardiovascular disease, potentially explaining the disappointing results of PDE5A inhibition in clinical trials. David Kass and colleagues now identify an alternative target, PDE9A, which specifically regulates natriuretic-peptide-coupled cGMP signalling, and is independent of nitric oxide. They show that PDE9A is upregulated in failing human hearts and that its inhibition in mice can reverse pre-established stress-induced heart disease. PDE9A inhibitors seem to be well tolerated in humans and are being investigated in clinical trials for neurocognitive disease. The new results suggest that these inhibitors may also find an application in heart disease. Cyclic guanosine monophosphate (cGMP) is a second messenger molecule that transduces nitric-oxide- and natriuretic-peptide-coupled signalling, stimulating phosphorylation changes by protein kinase G. Enhancing cGMP synthesis or blocking its degradation by phosphodiesterase type 5A (PDE5A) protects against cardiovascular disease1,2. However, cGMP stimulation alone is limited by counter-adaptions including PDE upregulation3. Furthermore, although PDE5A regulates nitric-oxide-generated cGMP4,5, nitric oxide signalling is often depressed by heart disease6. PDEs controlling natriuretic-peptide-coupled cGMP remain uncertain. Here we show that cGMP-selective PDE9A (refs 7, 8) is expressed in the mammalian heart, including humans, and is upregulated by hypertrophy and cardiac failure. PDE9A regulates natriuretic-peptide- rather than nitric-oxide-stimulated cGMP in heart myocytes and muscle, and its genetic or selective pharmacological inhibition protects against pathological responses to neurohormones, and sustained pressure-overload stress. PDE9A inhibition reverses pre-established heart disease independent of nitric oxide synthase (NOS) activity, whereas PDE5A inhibition requires active NOS. Transcription factor activation and phosphoproteome analyses of myocytes with each PDE selectively inhibited reveals substantial differential targeting, with phosphorylation changes from PDE5A inhibition being more sensitive to NOS activation. Thus, unlike PDE5A, PDE9A can regulate cGMP signalling independent of the nitric oxide pathway, and its role in stress-induced heart disease suggests potential as a therapeutic target.

1 December 2021 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
PDF file
Merry L LindseyMerry L Lindsey
Merry L Lindsey
KBKeith R. Brunt
Keith R. Brunt
JKJonathan A. Kirk
Jonathan A. Kirk
Petra KleinbongardPetra Kleinbongard
Petra Kleinbongard
JCJohn W. Calvert
John W. Calvert
ZKZamaneh Kassiri
Zamaneh Kassiri
Despite significant improvements in reperfusion strategies, acute coronary syndromes all too often culminate in a myocardial infarction (MI). The consequent MI can, in turn, lead to remodeling of the left ventricle (LV), the development of LV dysfunction, and ultimately progression to heart failure (HF). Accordingly, an improved understanding of the underlying mechanisms of MI remodeling and progression to HF is necessary. One common approach to examine MI pathology is with murine models that recapitulate components of the clinical context of acute coronary syndrome and subsequent MI. We evaluated the different approaches used to produce MI in mouse models and identified opportunities to consolidate methods, recognizing that reperfused and nonreperfused MI yield different responses. The overall goal in compiling this consensus statement is to unify best practices regarding mouse MI models to improve interpretation and allow comparative examination across studies and laboratories. These guidelines will help to establish rigor and reproducibility and provide increased potential for clinical translation. Listen to another corresponding podcast at https://ajpheart.podbean.com/e/guidelines-for-in-vivo-mouse-models-of-myocardial-infarction/ .

19 May 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
TMThomas G. Martin
Thomas G. Martin
VMValerie D. Myers
Valerie D. Myers
PDPraveen Dubey
Praveen Dubey
SDShubham Dubey
Shubham Dubey
EPEdith Perez
Edith Perez
JKJonathan A. Kirk
Jonathan A. Kirk
The association between reduced myofilament force-generating capacity (Fmax) and heart failure (HF) is clear, however the underlying molecular mechanisms are poorly understood. Here, we show impaired Fmax arises from reduced BAG3-mediated sarcomere turnover. Myofilament BAG3 expression decreases in human HF and positively correlates with Fmax. We confirm this relationship using BAG3 haploinsufficient mice, which display reduced Fmax and increased myofilament ubiquitination, suggesting impaired protein turnover. We show cardiac BAG3 operates via chaperone-assisted selective autophagy (CASA), conserved from skeletal muscle, and confirm sarcomeric CASA complex localization is BAG3/proteotoxic stress-dependent. Using mass spectrometry, we characterize the myofilament CASA interactome in the human heart and identify eight clients of BAG3-mediated turnover. To determine if increasing BAG3 expression in HF can restore sarcomere proteostasis/Fmax, HF mice were treated with rAAV9-BAG3. Gene therapy fully rescued Fmax and CASA protein turnover after four weeks. Our findings indicate BAG3-mediated sarcomere turnover is fundamental for myofilament functional maintenance.

29 May 2018 in Circulation
Verified
Journal Article
Open access
PDF file
SHSteven Hsu
Steven Hsu
KKKristen M. Kokkonen-Simon
Kristen M. Kokkonen-Simon
JKJonathan A. Kirk
Jonathan A. Kirk
TKTodd M. Kolb
Todd M. Kolb
RDRachel L. Damico
Rachel L. Damico
DKDavid A. Kass
David A. Kass
Background: Patients with systemic sclerosis (SSc)–associated pulmonary arterial hypertension (PAH) have a far worse prognosis than those with idiopathic PAH (IPAH). In the intact heart, SSc-PAH exhibits depressed rest and reserve right ventricular (RV) contractility compared with IPAH. We tested whether this disparity involves underlying differences in myofilament function. Methods: Cardiac myocytes were isolated from RV septal endomyocardial biopsies from patients with SSc-PAH, IPAH, or SSc with exertional dyspnea but no resting PAH (SSc-d); control RV septal tissue was obtained from nondiseased donor hearts (6–7 per group). Isolated myocyte passive length-tension and developed tension-calcium relationships were determined and correlated with in vivo RV function and reserve. RV septal fibrosis was also examined. Results: Myocyte passive stiffness from length-tension relations was similarly increased in IPAH and SSc-PAH compared with control, although SSc-PAH biopsies had more interstitial fibrosis. More striking disparities were found between active force-calcium relations. Compared with controls, maximal calcium-activated force (F max ) was 28% higher in IPAH but 37% lower in SSc-PAH. F max in SSc-d was intermediate between control and SSc-PAH. The calcium concentration required for half-maximal force (EC 50 ) was similar between control, IPAH, and SSc-d but lower in SSc-PAH. This disparity disappeared in myocytes incubated with the active catalytic subunit of protein kinase A. Myocyte F max directly correlated with in vivo RV contractility assessed by end-systolic elastance ( R 2 =0.46, P =0.002) and change in end-systolic elastance with exercise ( R 2 =0.49, P =0.008) and was inversely related with exercise-induced chamber dilation ( R 2 =0.63, P <0.002), which also was a marker of depressed contractile reserve. Conclusions: A primary defect in human SSc-PAH resides in depressed sarcomere function, whereas this is enhanced in IPAH. These disparities correlate with in vivo RV contractility and contractile reserve and are consistent with worse clinical outcomes in SSc-PAH. The existence of sarcomere disease before the development of resting PAH in patients with SSc-d suggests that earlier identification and intervention may prove useful.

9 October 2012 in Circulation
Verified
Journal Article
Closed access
PDF file
PZPingbo Zhang
Pingbo Zhang
JKJonathan A. Kirk
Jonathan A. Kirk
WJWeihua Ji
Weihua Ji
CRCristobal G. dos Remedios
Cristobal G. dos Remedios
DKDavid A. Kass
David A. Kass
AMAnne M. Murphy
Anne M. Murphy
Background—: Human cardiac troponin I is known to be phosphorylated at multiple amino acid residues by several kinases. Advances in mass spectrometry allow sensitive detection of known and novel phosphorylation sites and measurement of the level of phosphorylation simultaneously at each site in myocardial samples. Methods and Results—: On the basis of in silico prediction and liquid chromatography/mass spectrometry data, 14 phosphorylation sites on cardiac troponin I, including 6 novel residues (S4, S5, Y25, T50, T180, S198), were assessed in explanted hearts from end-stage heart failure transplantation patients with ischemic heart disease or idiopathic dilated cardiomyopathy and compared with samples obtained from nonfailing donor hearts (n=10 per group). Thirty mass spectrometry–based multiple reaction monitoring quantitative tryptic peptide assays were developed for each phosphorylatable and corresponding nonphosphorylated site. The results show that in heart failure there is a decrease in the extent of phosphorylation of the known protein kinase A sites (S22, S23) and other newly discovered phosphorylation sites located in the N-terminal extension of cardiac troponin I (S4, S5, Y25), an increase in phosphorylation of the protein kinase C sites (S41, S43, T142), and an increase in phosphorylation of the IT-arm domain residues (S76, T77) and C-terminal domain novel phosphorylation sites of cardiac troponin I (S165, T180, S198). In a canine dyssynchronous heart failure model, enhanced phosphorylation at 3 novel sites was found to decline toward control after resynchronization therapy. Conclusions—: Selective, functionally significant phosphorylation alterations occurred on individual residues of cardiac troponin I in heart failure, likely reflecting an imbalance in kinase/phosphatase activity. Such changes can be reversed by cardiac resynchronization.

27 June 2016 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
ANAnta Ngkelo
Anta Ngkelo
ARAdèle Richart
Adèle Richart
JKJonathan A. Kirk
Jonathan A. Kirk
PBPhilippe Bonnin
Philippe Bonnin
JVJose Vilar
Jose Vilar
JSJean-Sébastien Silvestre
Jean-Sébastien Silvestre
Acute myocardial infarction (MI) is a severe ischemic disease responsible for heart failure and sudden death. Inflammatory cells orchestrate postischemic cardiac remodeling after MI. Studies using mice with defective mast/stem cell growth factor receptor c-Kit have suggested key roles for mast cells (MCs) in postischemic cardiac remodeling. Because c-Kit mutations affect multiple cell types of both immune and nonimmune origin, we addressed the impact of MCs on cardiac function after MI, using the c-Kit–independent MC-deficient (Cpa3Cre/+) mice. In response to MI, MC progenitors originated primarily from white adipose tissue, infiltrated the heart, and differentiated into mature MCs. MC deficiency led to reduced postischemic cardiac function and depressed cardiomyocyte contractility caused by myofilament Ca2+ desensitization. This effect correlated with increased protein kinase A (PKA) activity and hyperphosphorylation of its targets, troponin I and myosin-binding protein C. MC-specific tryptase was identified to regulate PKA activity in cardiomyocytes via protease-activated receptor 2 proteolysis. This work reveals a novel function for cardiac MCs modulating cardiomyocyte contractility via alteration of PKA-regulated force–Ca2+ interactions in response to MI. Identification of this MC-cardiomyocyte cross-talk provides new insights on the cellular and molecular mechanisms regulating the cardiac contractile machinery and a novel platform for therapeutically addressable regulators.